BMJ Open Diabetes Research & Care
is an open access diabetes journal from the ADA and BMJ that strives to publish innovative studies on diabetes in all disciplines and therapeutic areas as quickly and transparently as possible.
Impact Factor: 3.7
Citescore: 9.3
All metrics >>
Latest Articles
Psychosocial research:
Diabetes-related distress over time and its associations with glucose levels in school-aged children1 June 2025
Emerging technologies, pharmacology and therapeutics:
Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England28 May 2025
Metabolism:
Differences in fat distribution between metabolically unhealthy people with normal weight versus obesity, NHANES 2011–201828 May 2025
Cardiovascular and metabolic risk:
Relationship between time-varying achieved HbA1c and risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE study6 May 2025
Emerging technologies, pharmacology and therapeutics:
CASPAR: a retrospective cohort study of the high-concentration capsaicin topical system in patients with painful diabetic peripheral neuropathy of the feet2 May 2025
Most Read Articles
Obesity studies:
Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects18 October 2024
Cardiovascular and metabolic risk:
Association between personality, lifestyle behaviors, and cardiovascular diseases in type 2 diabetes mellitus: a population-based cohort study of UK Biobank data10 September 2024
Epidemiology/Health services research:
Prevalence and risk factors for diabetic retinopathy at diagnosis of type 2 diabetes: an observational study of 77 681 patients from the Swedish National Diabetes Registry4 June 2024
Clinical care/Education/Nutrition:
A randomized, placebo-controlled study of chitosan gel for the treatment of chronic diabetic foot ulcers (the CHITOWOUND study)23 June 2024
Cardiovascular and metabolic risk:
Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA4 October 2024